<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00377312</url>
  </required_header>
  <id_info>
    <org_study_id>0606127</org_study_id>
    <secondary_id>R01DK073039</secondary_id>
    <nct_id>NCT00377312</nct_id>
  </id_info>
  <brief_title>7 Day Continuous Parathyroid Hormone IV Infusion</brief_title>
  <official_title>Determining the Maximal Safe Dose of a Continuous Infusion of Parathyroid Hormone(1-34): Effects on Bone Formation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Pittsburgh</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Pittsburgh</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Study consists of an eight day inpatient visit on the General Clinical Research Center. The
      investigators' specific aims are to:

        1. To define the maximum safe dose of a seven day continuous administration of parathyroid
           hormone [PTH(1-34)] in healthy human volunteers.

        2. To estimate the effect of a seven day continuous administration of parathyroid Hormone
           (PTH) in escalating doses on vitamin D metabolism, markers of bone turnover and
           fractional excretion of urine.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study will expand upon earlier infusions studies that demonstrated: 1) There is a
      dose-related increase in 1,25 (OH)2 vitamin D in response to PTHrP and PTH over multiple
      days. 2) There is a markedly attenuated vitamin D response to PTHrP compared to PTH,
      particularly during the second 24 hours. 3) The increase in 1,25 (OH)2 vitamin D is almost
      certainly responsible for the greater calcemic effect of PTH compared to PTHrP. 4) PTHrP is
      obviously a weaker agonist of 1,25 (OH)2 vitamin D but does not result in its suppression as
      is seen in Humoral Hypercalcemia of Malignancy (HHM). Thus, the suppression of 1,25 (OH)2
      vitamin D seen in HHM remained unexplained. In addition to assessing the effects of an
      infusion of PTHrP and PTH on calcium handling and 1,25(OH)2 vitamin D, we also measured their
      effects on markers of bone turnover. Given the clinical observations seen in
      Hyperparathyroidism (HPT) and HHM, we anticipated that PTH would stimulate both bone
      resorption and formation, while PTHrP would stimulate bone resorption but inhibit formation.
      However, we observed that infusions of PTHrP and PTH resulted in an equivalent, rapid
      increase in bone resorption as measured by N-telopeptide (NTx) and C-telopeptide (CTx), as
      well as a progressive decline in bone formation. There was no difference between PTH and
      PTHrP. We assumed that formation would ultimately increase with additional time, as seen in
      HPT, and therefore examined an additional group of subjects infused with PTHrP for 96 hours.
      However, N-terminal propeptide of type 1 procollagen (P1NP) continued to decline even further
      as is seen in HHM in contrast to HPT. We have not yet studied longer infusions of PTH.

      One of the reasons for doing this pilot study is to determine the optimal dosing of PTH over
      a week period of time. Intravenous PTH has never been infused into human beings for prolonged
      periods of time. The investigators question whether a prolonged continuous intravenous
      infusion of PTH will lead to a sustained and progressive suppression of bone formation as
      occurs in HHM or an increase in bone formation as occurs in HPT. They also want to assess the
      direct influence of long-term continuous PTH infusions on plasma 1,25 (OH)2 vitamin D
      regulation in healthy human volunteers. We have shown in our previous studies that doses of 8
      picomoles (pmol)/kg/hr PTH given over 48 hours result in sustained mild serum hypercalcemia,
      with serum calcium seeming to plateau in the range of 11 - 11.5 mg/dL after 48 hours. A dose
      of 8 picomoles (pmol)/kg/hr has also been shown to cause desirable effects on serum 1,25(OH)2
      vitamin D and markers of bone turnover, and may therefore be the &quot;ideal&quot; dose. However, we do
      not know whether serum calcium will plateau after an infusion of 48 hours with escalating
      doses or whether it will continue to increase over seven days.

      To determine what will happen with a prolonged infusion, we plan to start with doses lower
      than 8 picomoles (pmol)/kg/hr, and then gradually increase the dose of PTH in successive
      groups of subjects. In the event of a significant adverse effect, immediate action will be
      taken to reverse it. Protocols will be in place to follow in the event of expected adverse
      events such as hypotension, nausea, and muscle cramping. Severe sudden side effects are not
      anticipated; however, mild easily reversible side effects are to be expected as an outcome in
      order to determine the optimal dose of PTH. This study has been approved by the NIH and the
      Data Safety Monitoring Board (DSMB).

      Seventy five normal healthy men and women will be screened for an eight day in-patient
      admission to the General Clinical Research Center (GCRC). Thirty evaluable research
      participants will receive a seven day infusion of a predetermined dose of PTH. Vitals signs,
      blood pressure, blood and urine lab results will be monitored frequently as per the study
      flow sheet. The starting dose of PTH, 2 picomoles (pmol)/kg, will be given to three normal
      healthy subjects. The dose will be escalated in increments with successive groups of three
      subjects each, until early adverse effects (mild hypercalcemia, postural hypotension,
      tachycardia) are seen. This dose will then be used in future studies. The investigators with
      this study are trying to discover if a prolonged continuous intravenous infusion of PTH will
      lead to a sustained and progressive suppression of bone formation as occurs in HHM or an
      increase in bone formation as occurs in HPT.

      Subject Population will consist of healthy young adults, ages 24-35 years, as in our other
      safety and physiologic studies. It is anticipated that we will need to screen 75 subjects in
      order to obtain 30 evaluable subjects.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2006</start_date>
  <completion_date type="Actual">December 2007</completion_date>
  <primary_completion_date type="Actual">December 2007</primary_completion_date>
  <phase>Early Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Participants With Dose Limiting Toxicity</measure>
    <time_frame>12 hours after the infusion was started then q 8 hours for 7 days</time_frame>
    <description>DLT was defined as achieving one major criterion or two minor criteria rated at ≥ 2 on a scale of 0-5. The major criteria were defined as symptomatic orthostatic hypotension (systolic BP fall &gt;30 mm/hg), tachycardia (pulse &gt; 120), hypertension (systolic BP &gt;160 mm/hg on 2 occasions), hypercalcemia (serum calcium ≥ 12 mg/dl), and hypophosphatemia (serum phosphorous &lt; 1.5 mg/dl). Minor criteria included symptoms such as flushing, nausea, abdominal or muscle cramps, dizziness, lightheadedness, palpitations, etc.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Total Serum Calcium</measure>
    <time_frame>12 hours after the infusion was started then q 8 hours for 7 days, Follow-up 1 week after infusion complete</time_frame>
    <description>mg/dl</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Ionized Serum Calcium</measure>
    <time_frame>12 hours after the infusion was started then q 8 hours for 7 days, Follow-up 1 week after infusion complete</time_frame>
    <description>mg/dl</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Serum Phosphorous</measure>
    <time_frame>12 hours after the infusion was started then q 8 hours for 7 days, Follow-up 1 week after infusion complete</time_frame>
    <description>mg/dl</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>1,25 Vitamin D</measure>
    <time_frame>baseline, daily up to Day 8 and follow-up</time_frame>
    <description>pg/ml</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Parathyroid Hormone (1-84)</measure>
    <time_frame>baseline, daily up to Day 8 and follow-up</time_frame>
    <description>pg/ml</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fractional Excretion of Calcium</measure>
    <time_frame>baseline and daily</time_frame>
    <description>% = (S Creatinine X U Calcium)/(S Calcium X U Creatinine)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>24 Hour Urine Calcium</measure>
    <time_frame>24 hours period from Day 7 to Day 8</time_frame>
    <description>mg/gm creatinine</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tubular Maximum for Phosphorous</measure>
    <time_frame>baseline and daily</time_frame>
    <description>mg/dl</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum Amino-terminal of Collagen- (sNTX)</measure>
    <time_frame>baseline, daily, one week follow-up</time_frame>
    <description>% change from baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum Carboxy-terminal of Collagen- 1(sCTX)</measure>
    <time_frame>baseline, daily, one week follow-up</time_frame>
    <description>% change from baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Amino-terminal Peptides of Procollagen- 1(P1NP)</measure>
    <time_frame>baseline, daily, one week follow-up</time_frame>
    <description>% change from baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Bone Specific Alkaline Phosphatase (BSAP)</measure>
    <time_frame>baseline, daily, one week follow-up</time_frame>
    <description>% change from baseline</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">11</enrollment>
  <condition>Osteoporosis</condition>
  <condition>Bone Diseases, Endocrine</condition>
  <condition>Hyperparathyroidism</condition>
  <arm_group>
    <arm_group_label>Group 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Parathyroid Hormone (PTH) (1-34) 2 picomols/kg/hr for one week.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Parathyroid Hormone (PTH) (1-34)4 picomols/kg/hr for one week.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Parathyroid Hormone (1-34)</intervention_name>
    <description>PTH(1-34) IV given over a one week period</description>
    <arm_group_label>Group 1</arm_group_label>
    <arm_group_label>Group 2</arm_group_label>
    <other_name>IND 60,979</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy Caucasian, Hispanic or Asian subjects

          -  Males and Females

          -  Non-smoker

          -  Ages 24 - 35 years old

          -  Subjects will be recruited either from the employee pool of the University of
             Pittsburgh or the University of Pittsburgh Medical Center (UPMC), or the general
             population living in the vicinity.

          -  Participation in this study by an employee or a potential employee at the University
             of Pittsburgh or UPMC has no effect on their employment or potential employment.

          -  Participants in the study will be required to discontinue all vitamins and health food
             supplements two weeks prior to the study.

        Exclusion Criteria:

          -  Cardiac, hypertensive, vascular, renal (serum creatinine of &gt;1.5), pulmonary,
             endocrine, musculoskeletal, hepatic, hematologic or malignant or rheumatologic disease

          -  Body Mass Index (BMI) &gt; 30,

          -  Anemia (hematocrit less than 36% in women, less than 40% in men),

          -  Pregnancy (all women will have a urine pregnancy test performed immediately before
             starting the study and must not be pregnant)

          -  Significant alcohol or drug abuse or

          -  Baseline hypotension (systolic blood pressure less than 90 mm/Hg).

          -  Subjects will be excluded for abnormal levels of any of the screening labs including:
             ionized and total serum calcium, phosphorus, creatinine, albumin, 25-hydroxyvitamin D,
             and PTH. Pregnancy

          -  Subjects taking any chronic medications except oral contraceptives and stable doses of
             thyroid hormone, or those who have received any investigational drug in past 90 days
             will be excluded from the study.

          -  Subjects may not participate in this study more than once.

          -  Any subject who has previously received PTH or PTHrP, a related peptide, may not
             participate in this study.

        Minority Inclusion/Exclusion Statement: We will not include African-Americans because this
        group has been demonstrated by a number of investigators to display resistance to PTH, and
        may create wider statistical variation and a need for larger numbers of study subjects per
        group.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>24 Years</minimum_age>
    <maximum_age>35 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mara J. Horwitz, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Pittsburgh</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Pittsburgh Medical Center</name>
      <address>
        <city>Pittsburgh,</city>
        <state>Pennsylvania</state>
        <zip>15213</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.clinicalresearch.pitt.edu</url>
    <description>University of Pittsburgh's clinical research study website.</description>
  </link>
  <reference>
    <citation>Horwitz MJ, Tedesco MB, Gundberg C, Garcia-Ocana A, Stewart AF. Short-term, high-dose parathyroid hormone-related protein as a skeletal anabolic agent for the treatment of postmenopausal osteoporosis. J Clin Endocrinol Metab. 2003 Feb;88(2):569-75.</citation>
    <PMID>12574182</PMID>
  </reference>
  <reference>
    <citation>Syed MA, Horwitz MJ, Tedesco MB, Garcia-Ocaña A, Wisniewski SR, Stewart AF. Parathyroid hormone-related protein-(1--36) stimulates renal tubular calcium reabsorption in normal human volunteers: implications for the pathogenesis of humoral hypercalcemia of malignancy. J Clin Endocrinol Metab. 2001 Apr;86(4):1525-31.</citation>
    <PMID>11297578</PMID>
  </reference>
  <reference>
    <citation>Horwitz MJ, Tedesco MB, Sereika SM, Hollis BW, Garcia-Ocaña A, Stewart AF. Direct comparison of sustained infusion of human parathyroid hormone-related protein-(1-36) [hPTHrP-(1-36)] versus hPTH-(1-34) on serum calcium, plasma 1,25-dihydroxyvitamin D concentrations, and fractional calcium excretion in healthy human volunteers. J Clin Endocrinol Metab. 2003 Apr;88(4):1603-9.</citation>
    <PMID>12679445</PMID>
  </reference>
  <reference>
    <citation>Everhart-Caye M, Inzucchi SE, Guinness-Henry J, Mitnick MA, Stewart AF. Parathyroid hormone (PTH)-related protein(1-36) is equipotent to PTH(1-34) in humans. J Clin Endocrinol Metab. 1996 Jan;81(1):199-208.</citation>
    <PMID>8550752</PMID>
  </reference>
  <reference>
    <citation>Henry JG, Mitnick M, Dann PR, Stewart AF. Parathyroid hormone-related protein-(1-36) is biologically active when administered subcutaneously to humans. J Clin Endocrinol Metab. 1997 Mar;82(3):900-6.</citation>
    <PMID>9062504</PMID>
  </reference>
  <reference>
    <citation>Plotkin H, Gundberg C, Mitnick M, Stewart AF. Dissociation of bone formation from resorption during 2-week treatment with human parathyroid hormone-related peptide-(1-36) in humans: potential as an anabolic therapy for osteoporosis. J Clin Endocrinol Metab. 1998 Aug;83(8):2786-91.</citation>
    <PMID>9709948</PMID>
  </reference>
  <reference>
    <citation>Stewart AF, Cain RL, Burr DB, Jacob D, Turner CH, Hock JM. Six-month daily administration of parathyroid hormone and parathyroid hormone-related protein peptides to adult ovariectomized rats markedly enhances bone mass and biomechanical properties: a comparison of human parathyroid hormone 1-34, parathyroid hormone-related protein 1-36, and SDZ-parathyroid hormone 893. J Bone Miner Res. 2000 Aug;15(8):1517-25.</citation>
    <PMID>10934650</PMID>
  </reference>
  <reference>
    <citation>Horwitz MJ, Tedesco MB, Sereika SM, Syed MA, Garcia-Ocaña A, Bisello A, Hollis BW, Rosen CJ, Wysolmerski JJ, Dann P, Gundberg C, Stewart AF. Continuous PTH and PTHrP infusion causes suppression of bone formation and discordant effects on 1,25(OH)2 vitamin D. J Bone Miner Res. 2005 Oct;20(10):1792-803. Epub 2005 Jun 6.</citation>
    <PMID>16160737</PMID>
  </reference>
  <reference>
    <citation>Horwitz MJ, Tedesco MB, Sereika SM, Garcia-Ocaña A, Bisello A, Hollis BW, Gundberg C, Stewart AF. Safety and tolerability of subcutaneous PTHrP(1-36) in healthy human volunteers: a dose escalation study. Osteoporos Int. 2006 Feb;17(2):225-30. Epub 2005 Sep 7.</citation>
    <PMID>16151606</PMID>
  </reference>
  <reference>
    <citation>Jüppner H, Abou-Samra AB, Freeman M, Kong XF, Schipani E, Richards J, Kolakowski LF Jr, Hock J, Potts JT Jr, Kronenberg HM, et al. A G protein-linked receptor for parathyroid hormone and parathyroid hormone-related peptide. Science. 1991 Nov 15;254(5034):1024-6.</citation>
    <PMID>1658941</PMID>
  </reference>
  <reference>
    <citation>Orloff JJ, Wu TL, Heath HW, Brady TG, Brines ML, Stewart AF. Characterization of canine renal receptors for the parathyroid hormone-like protein associated with humoral hypercalcemia of malignancy. J Biol Chem. 1989 Apr 15;264(11):6097-103.</citation>
    <PMID>2539369</PMID>
  </reference>
  <reference>
    <citation>Orloff JJ, Ribaudo AE, McKee RL, Rosenblatt M, Stewart AF. A pharmacological comparison of parathyroid hormone receptors in human bone and kidney. Endocrinology. 1992 Oct;131(4):1603-11.</citation>
    <PMID>1327716</PMID>
  </reference>
  <reference>
    <citation>Samuels MH, Veldhuis J, Cawley C, Urban RJ, Luther M, Bauer R, Mundy G. Pulsatile secretion of parathyroid hormone in normal young subjects: assessment by deconvolution analysis. J Clin Endocrinol Metab. 1993 Aug;77(2):399-403.</citation>
    <PMID>8345044</PMID>
  </reference>
  <reference>
    <citation>Prank K, Nowlan SJ, Harms HM, Kloppstech M, Brabant G, Hesch RD, Sejnowski TJ. Time series prediction of plasma hormone concentration. Evidence for differences in predictability of parathyroid hormone secretion between osteoporotic patients and normal controls. J Clin Invest. 1995 Jun;95(6):2910-9.</citation>
    <PMID>7769133</PMID>
  </reference>
  <reference>
    <citation>Schmitt CP, Obry J, Feneberg R, Veldhuis JD, Mehls O, Ritz E, Schaefer F. Beta1-adrenergic blockade augments pulsatile PTH secretion in humans. J Am Soc Nephrol. 2003 Dec;14(12):3245-50.</citation>
    <PMID>14638923</PMID>
  </reference>
  <reference>
    <citation>Chapotot F, Gronfier C, Spiegel K, Luthringer R, Brandenberger G. Relationships between intact parathyroid hormone 24-hour profiles, sleep-wake cycle, and sleep electroencephalographic activity in man. J Clin Endocrinol Metab. 1996 Oct;81(10):3759-65.</citation>
    <PMID>8855835</PMID>
  </reference>
  <reference>
    <citation>Harms HM, Schlinke E, Neubauer O, Kayser C, Wüstermann PR, Horn R, Külpmann WR, von zur Mühlen A, Hesch RD. Pulse amplitude and frequency modulation of parathyroid hormone in primary hyperparathyroidism. J Clin Endocrinol Metab. 1994 Jan;78(1):53-7.</citation>
    <PMID>8288713</PMID>
  </reference>
  <reference>
    <citation>Ledger GA, Burritt MF, Kao PC, O'Fallon WM, Riggs BL, Khosla S. Role of parathyroid hormone in mediating nocturnal and age-related increases in bone resorption. J Clin Endocrinol Metab. 1995 Nov;80(11):3304-10.</citation>
    <PMID>7593443</PMID>
  </reference>
  <reference>
    <citation>el-Hajj Fuleihan G, Klerman EB, Brown EN, Choe Y, Brown EM, Czeisler CA. The parathyroid hormone circadian rhythm is truly endogenous--a general clinical research center study. J Clin Endocrinol Metab. 1997 Jan;82(1):281-6.</citation>
    <PMID>8989274</PMID>
  </reference>
  <reference>
    <citation>Plawner LL, Philbrick WM, Burtis WJ, Broadus AE, Stewart AF. Cell type-specific secretion of parathyroid hormone-related protein via the regulated versus the constitutive secretory pathway. J Biol Chem. 1995 Jun 9;270(23):14078-84.</citation>
    <PMID>7775469</PMID>
  </reference>
  <reference>
    <citation>Fraher LJ, Hodsman AB, Jonas K, Saunders D, Rose CI, Henderson JE, Hendy GN, Goltzman D. A comparison of the in vivo biochemical responses to exogenous parathyroid hormone-(1-34) [PTH-(1-34)] and PTH-related peptide-(1-34) in man. J Clin Endocrinol Metab. 1992 Aug;75(2):417-23.</citation>
    <PMID>1322424</PMID>
  </reference>
  <reference>
    <citation>Burtis WJ, Wu T, Bunch C, Wysolmerski JJ, Insogna KL, Weir EC, Broadus AE, Stewart AF. Identification of a novel 17,000-dalton parathyroid hormone-like adenylate cyclase-stimulating protein from a tumor associated with humoral hypercalcemia of malignancy. J Biol Chem. 1987 May 25;262(15):7151-6.</citation>
    <PMID>3584110</PMID>
  </reference>
  <reference>
    <citation>Stewart AF, Wu T, Goumas D, Burtis WJ, Broadus AE. N-terminal amino acid sequence of two novel tumor-derived adenylate cyclase-stimulating proteins: identification of parathyroid hormone-like and parathyroid hormone-unlike domains. Biochem Biophys Res Commun. 1987 Jul 31;146(2):672-8.</citation>
    <PMID>3619898</PMID>
  </reference>
  <reference>
    <citation>Wu TL, Vasavada RC, Yang K, Massfelder T, Ganz M, Abbas SK, Care AD, Stewart AF. Structural and physiologic characterization of the mid-region secretory species of parathyroid hormone-related protein. J Biol Chem. 1996 Oct 4;271(40):24371-81.</citation>
    <PMID>8798692</PMID>
  </reference>
  <reference>
    <citation>Cosman F, Shen V, Xie F, Seibel M, Ratcliffe A, Lindsay R. Estrogen protection against bone resorbing effects of parathyroid hormone infusion. Assessment by use of biochemical markers. Ann Intern Med. 1993 Mar 1;118(5):337-43. Erratum in: Ann Intern Med 1994 Apr 15;120(8):698.</citation>
    <PMID>8430979</PMID>
  </reference>
  <reference>
    <citation>Hodsman AB, Fraher LJ, Ostbye T, Adachi JD, Steer BM. An evaluation of several biochemical markers for bone formation and resorption in a protocol utilizing cyclical parathyroid hormone and calcitonin therapy for osteoporosis. J Clin Invest. 1993 Mar;91(3):1138-48.</citation>
    <PMID>8450043</PMID>
  </reference>
  <verification_date>March 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 14, 2006</study_first_submitted>
  <study_first_submitted_qc>September 14, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 18, 2006</study_first_posted>
  <results_first_submitted>April 25, 2014</results_first_submitted>
  <results_first_submitted_qc>March 18, 2016</results_first_submitted_qc>
  <results_first_posted type="Estimate">March 22, 2016</results_first_posted>
  <last_update_submitted>March 18, 2016</last_update_submitted>
  <last_update_submitted_qc>March 18, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 22, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Pittsburgh</investigator_affiliation>
    <investigator_full_name>Mara Horwitz</investigator_full_name>
    <investigator_title>Associate Professor of Medicne</investigator_title>
  </responsible_party>
  <keyword>Endocrine System Diseases</keyword>
  <keyword>MusculoSkeletal System Disease</keyword>
  <keyword>Hormone</keyword>
  <keyword>Physiologic Properties</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Osteoporosis</mesh_term>
    <mesh_term>Hyperparathyroidism</mesh_term>
    <mesh_term>Bone Diseases</mesh_term>
    <mesh_term>Bone Diseases, Endocrine</mesh_term>
    <mesh_term>Endocrine System Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hormones</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Starting in October 2006, 19 Healthy caucasian males &amp; females between 24 - 35 yrs were screened. By November 2007 11 subjects were randomized and 10 completed the one week infusion study which was done on the Clinical and Translational Research Clinic (CTRC) at the University of Pittsburgh Medical Center (UPMC).</recruitment_details>
      <pre_assignment_details>Candidates were non-smokers and females had negative pregnancy tests. Those on chronic medications with the exception of oral contraceptives or stable thyroid hormone replacement were excluded. Body mass index had to be less than 30, and all had normal screening labs.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Group 1</title>
          <description>PTH (1-34) 2 picomoles (pmols)/kg/hr</description>
        </group>
        <group group_id="P2">
          <title>Group 2</title>
          <description>PTH (1-34) 4 picomoles (pmols)/kg/hr</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="5"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="4"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Eleven subjects received parathyroid hormone (1-34) infusions intravenously for one week.</population>
      <group_list>
        <group group_id="B1">
          <title>Parathyroid Hormone - 2 Picomoles/kg/hr.</title>
          <description>Subjects initially entering the study receive study drug Parathyroid Hormone (1-34) in intravenous doses beginning at 2 picomoles/kg/hr. Doses will be slowly and safely escalated in groups of 3 subjects.</description>
        </group>
        <group group_id="B2">
          <title>Parathyroid Hormone(1-34) - 4 Picomoles/kg/hr</title>
          <description>Subjects received Parathyroid Hormone (1-34)intravenously at 4 picomoles/kg/hr.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="6"/>
            <count group_id="B2" value="5"/>
            <count group_id="B3" value="11"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Participants With Dose Limiting Toxicity</title>
        <description>DLT was defined as achieving one major criterion or two minor criteria rated at ≥ 2 on a scale of 0-5. The major criteria were defined as symptomatic orthostatic hypotension (systolic BP fall &gt;30 mm/hg), tachycardia (pulse &gt; 120), hypertension (systolic BP &gt;160 mm/hg on 2 occasions), hypercalcemia (serum calcium ≥ 12 mg/dl), and hypophosphatemia (serum phosphorous &lt; 1.5 mg/dl). Minor criteria included symptoms such as flushing, nausea, abdominal or muscle cramps, dizziness, lightheadedness, palpitations, etc.</description>
        <time_frame>12 hours after the infusion was started then q 8 hours for 7 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Group 1</title>
            <description>PTH(1-34) 2 picomols (pmols)/kg/hr</description>
          </group>
          <group group_id="O2">
            <title>Group 2</title>
            <description>PTH(1-34) 4 picomoles/kg/hr for one week</description>
          </group>
        </group_list>
        <measure>
          <title>Participants With Dose Limiting Toxicity</title>
          <description>DLT was defined as achieving one major criterion or two minor criteria rated at ≥ 2 on a scale of 0-5. The major criteria were defined as symptomatic orthostatic hypotension (systolic BP fall &gt;30 mm/hg), tachycardia (pulse &gt; 120), hypertension (systolic BP &gt;160 mm/hg on 2 occasions), hypercalcemia (serum calcium ≥ 12 mg/dl), and hypophosphatemia (serum phosphorous &lt; 1.5 mg/dl). Minor criteria included symptoms such as flushing, nausea, abdominal or muscle cramps, dizziness, lightheadedness, palpitations, etc.</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
                <count group_id="O2" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Total Serum Calcium</title>
        <description>mg/dl</description>
        <time_frame>12 hours after the infusion was started then q 8 hours for 7 days, Follow-up 1 week after infusion complete</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Group 1</title>
            <description>PTH(1-34) 2 picomols (pmols)/kg/hr</description>
          </group>
          <group group_id="O2">
            <title>Group 2</title>
            <description>PTH(1-34) 4 picomoles/kg/hr for one week</description>
          </group>
        </group_list>
        <measure>
          <title>Total Serum Calcium</title>
          <description>mg/dl</description>
          <units>mg/dl</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
                <count group_id="O2" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.33" spread="0.20"/>
                    <measurement group_id="O2" value="9.11" spread="0.16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>11P Day 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.56" spread="0.19"/>
                    <measurement group_id="O2" value="9.78" spread="0.21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>7 A Day 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.74" spread="0.15"/>
                    <measurement group_id="O2" value="10.06" spread="0.22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>3P Day 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.14" spread="0.18"/>
                    <measurement group_id="O2" value="10.30" spread="0.26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>11P Day 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.84" spread="0.15"/>
                    <measurement group_id="O2" value="10.38" spread="0.37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>7A Day 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.10" spread="0.17"/>
                    <measurement group_id="O2" value="10.52" spread="0.34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>3P Day 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.32" spread="0.26"/>
                    <measurement group_id="O2" value="10.66" spread="0.42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>11P Day 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.72" spread="0.31"/>
                    <measurement group_id="O2" value="9.94" spread="0.26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>7A Day 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.04" spread="0.33"/>
                    <measurement group_id="O2" value="9.88" spread="0.17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>3P Day 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.94" spread="0.30"/>
                    <measurement group_id="O2" value="9.94" spread="0.23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>11P Day 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.54" spread="0.29"/>
                    <measurement group_id="O2" value="9.56" spread="0.19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>7A Day 5</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.16" spread="0.47"/>
                    <measurement group_id="O2" value="9.64" spread="0.28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>3P Day 5</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.26" spread="0.38"/>
                    <measurement group_id="O2" value="9.72" spread="0.31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>11P Day 5</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.82" spread="0.37"/>
                    <measurement group_id="O2" value="9.46" spread="0.23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>7A Day 6</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.18" spread="0.33"/>
                    <measurement group_id="O2" value="9.92" spread="0.23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>3P Day 6</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.28" spread="0.40"/>
                    <measurement group_id="O2" value="10.28" spread="0.19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>11P Day 6</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.56" spread="0.37"/>
                    <measurement group_id="O2" value="9.60" spread="0.31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>7A Day 7</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.18" spread="0.35"/>
                    <measurement group_id="O2" value="9.90" spread="0.17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>3P Day 7</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.02" spread="0.39"/>
                    <measurement group_id="O2" value="9.98" spread="0.19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>11P Day 7</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.82" spread="0.33"/>
                    <measurement group_id="O2" value="10.03" spread="0.18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>7A Day 8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.38" spread="0.31"/>
                    <measurement group_id="O2" value="10.50" spread="0.22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>FOLLOW-UP</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.50" spread="0.20"/>
                    <measurement group_id="O2" value="9.50" spread="0.12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>The study was designed as a standard dose-escalation study, dose-finding pilot study. The primary outcome measures were safety (hypercalcemia, hypophosphatemia and symptoms/hemodynamic measurements). A modified Fibronacci dose-escalation scheme was employed.</non_inferiority_desc>
            <p_value>&lt;.0001</p_value>
            <p_value_desc>The reported p-value corresponds to the increase over time for the PTH 2 pmol group.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>The level of statistical significance was set at .05 (two-tailed)</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Ionized Serum Calcium</title>
        <description>mg/dl</description>
        <time_frame>12 hours after the infusion was started then q 8 hours for 7 days, Follow-up 1 week after infusion complete</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Group 1</title>
            <description>PTH(1-34) 2 picomols (pmols)/kg/hr</description>
          </group>
          <group group_id="O2">
            <title>Group 2</title>
            <description>PTH(1-34) 4 picomoles/kg/hr for one week</description>
          </group>
        </group_list>
        <measure>
          <title>Ionized Serum Calcium</title>
          <description>mg/dl</description>
          <units>mg/dl</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
                <count group_id="O2" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.72" spread="0.10"/>
                    <measurement group_id="O2" value="4.52" spread="0.05"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>11P Day 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.93" spread="0.14"/>
                    <measurement group_id="O2" value="4.54" spread="0.18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>7 A Day 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.17" spread="0.09"/>
                    <measurement group_id="O2" value="5.04" spread="0.11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>3P Day 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.08" spread="0.06"/>
                    <measurement group_id="O2" value="5.01" spread="0.12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>11P Day 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.01" spread="0.15"/>
                    <measurement group_id="O2" value="4.97" spread="0.17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>7A Day 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.21" spread="0.19"/>
                    <measurement group_id="O2" value="5.22" spread="0.19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>3P Day 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.08" spread="0.09"/>
                    <measurement group_id="O2" value="5.11" spread="0.20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>11P Day 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.80" spread="0.17"/>
                    <measurement group_id="O2" value="4.82" spread="0.07"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>7A Day 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.10" spread="0.09"/>
                    <measurement group_id="O2" value="4.90" spread="0.08"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>3P Day 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.86" spread="0.17"/>
                    <measurement group_id="O2" value="4.77" spread="0.09"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>11P Day 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.93" spread="0.15"/>
                    <measurement group_id="O2" value="4.70" spread="0.06"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>7A Day 5</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.18" spread="0.24"/>
                    <measurement group_id="O2" value="4.84" spread="0.05"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>3P Day 5</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.03" spread="0.18"/>
                    <measurement group_id="O2" value="4.91" spread="0.18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>11P Day 5</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.90" spread="0.16"/>
                    <measurement group_id="O2" value="4.68" spread="0.11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>7A Day 6</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.29" spread="0.20"/>
                    <measurement group_id="O2" value="4.95" spread="0.13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>3P Day 6</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.17" spread="0.13"/>
                    <measurement group_id="O2" value="4.89" spread="0.08"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>11P Day 6</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.02" spread="0.18"/>
                    <measurement group_id="O2" value="4.82" spread="0.14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>7A Day 7</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.20" spread="0.14"/>
                    <measurement group_id="O2" value="4.99" spread="0.19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>3P Day 7</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.89" spread="0.12"/>
                    <measurement group_id="O2" value="4.88" spread="0.18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>11P Day 7</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.15" spread="0.19"/>
                    <measurement group_id="O2" value="4.86" spread="0.14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>7A Day 8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.34" spread="0.18"/>
                    <measurement group_id="O2" value="5.28" spread="0.16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>FOLLOW-UP</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.79" spread="0.05"/>
                    <measurement group_id="O2" value="4.70" spread="0.12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>The study was designed as a standard dose-escalation study, dose-finding pilot study. The primary outcome measures were safety (hypercalcemia, hypophosphatemia and symptoms/hemodynamic measurements). A modified Fibronacci dose-escalation scheme was employed.</non_inferiority_desc>
            <p_value>&lt;.0001</p_value>
            <p_value_desc>The reported p-value corresponds to the increase over time for the PTH 2 pmol group.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>The level of statistical significance was set at .05 (two-tailed)</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Serum Phosphorous</title>
        <description>mg/dl</description>
        <time_frame>12 hours after the infusion was started then q 8 hours for 7 days, Follow-up 1 week after infusion complete</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Group 1</title>
            <description>PTH(1-34) 2 picomols (pmols)/kg/hr</description>
          </group>
          <group group_id="O2">
            <title>Group 2</title>
            <description>PTH(1-34) 4 picomoles/kg/hr for one week</description>
          </group>
        </group_list>
        <measure>
          <title>Serum Phosphorous</title>
          <description>mg/dl</description>
          <units>mg/dl</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
                <count group_id="O2" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.51" spread="0.30"/>
                    <measurement group_id="O2" value="3.45" spread="0.28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>11P Day 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.16" spread="0.12"/>
                    <measurement group_id="O2" value="3.78" spread="0.19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>7 A Day 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.78" spread="0.15"/>
                    <measurement group_id="O2" value="3.68" spread="0.16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>3P Day 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.82" spread="0.15"/>
                    <measurement group_id="O2" value="3.44" spread="0.24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>11P Day 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.86" spread="0.12"/>
                    <measurement group_id="O2" value="3.78" spread="0.11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>7A Day 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.68" spread="0.16"/>
                    <measurement group_id="O2" value="3.58" spread="0.15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>3P Day 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.68" spread="0.18"/>
                    <measurement group_id="O2" value="3.28" spread="0.12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>11P Day 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.86" spread="0.09"/>
                    <measurement group_id="O2" value="3.60" spread="0.23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>7A Day 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.58" spread="0.17"/>
                    <measurement group_id="O2" value="3.64" spread="0.18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>3P Day 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.38" spread="0.16"/>
                    <measurement group_id="O2" value="3.22" spread="0.16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>11P Day 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.76" spread="0.07"/>
                    <measurement group_id="O2" value="3.52" spread="0.24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>7A Day 5</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.56" spread="0.14"/>
                    <measurement group_id="O2" value="3.72" spread="0.23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>3P Day 5</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.70" spread="0.20"/>
                    <measurement group_id="O2" value="3.22" spread="0.24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>11P Day 5</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.56" spread="0.10"/>
                    <measurement group_id="O2" value="3.64" spread="0.21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>7A Day 6</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.86" spread="0.12"/>
                    <measurement group_id="O2" value="3.60" spread="0.09"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>3P Day 6</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.78" spread="0.21"/>
                    <measurement group_id="O2" value="3.03" spread="0.23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>11P Day 6</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.70" spread="0.16"/>
                    <measurement group_id="O2" value="3.63" spread="0.09"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>7A Day 7</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.70" spread="0.22"/>
                    <measurement group_id="O2" value="3.90" spread="0.18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>3P Day 7</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.12" spread="0.17"/>
                    <measurement group_id="O2" value="3.18" spread="0.11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>11P Day 7</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.48" spread="0.11"/>
                    <measurement group_id="O2" value="3.55" spread="0.21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>7A Day 8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.82" spread="0.19"/>
                    <measurement group_id="O2" value="3.80" spread="0.09"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>FOLLOW-UP</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.12" spread="0.18"/>
                    <measurement group_id="O2" value="3.64" spread="0.28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>The study was designed as a standard dose-escalation study, dose-finding pilot study. The primary outcome measures were safety (hypercalcemia, hypophosphatemia and symptoms/hemodynamic measurements). A modified Fibronacci dose-escalation scheme was employed.</non_inferiority_desc>
            <p_value>&gt;0.05</p_value>
            <p_value_desc>The reported p-value corresponds to change over time for the PTH 2 and PTH 4 pmol groups</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>The level of statistical significance was set at .05 (two-tailed)</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>1,25 Vitamin D</title>
        <description>pg/ml</description>
        <time_frame>baseline, daily up to Day 8 and follow-up</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Group 1</title>
            <description>PTH(1-34) 2 picomols (pmols)/kg/hr</description>
          </group>
          <group group_id="O2">
            <title>Group 2</title>
            <description>PTH(1-34) 4 picomoles/kg/hr for one week</description>
          </group>
        </group_list>
        <measure>
          <title>1,25 Vitamin D</title>
          <description>pg/ml</description>
          <units>pg/ml</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
                <count group_id="O2" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="37.78" spread="4.71"/>
                    <measurement group_id="O2" value="39.18" spread="5.82"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="40.90" spread="2.78"/>
                    <measurement group_id="O2" value="42.72" spread="7.60"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="35.68" spread="2.94"/>
                    <measurement group_id="O2" value="41.74" spread="6.39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="27.70" spread="7.57"/>
                    <measurement group_id="O2" value="34.72" spread="6.91"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 5</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="36.16" spread="2.38"/>
                    <measurement group_id="O2" value="31.53" spread="4.78"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 6</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="38.00" spread="3.13"/>
                    <measurement group_id="O2" value="35.68" spread="3.39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 7</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="32.18" spread="3.41"/>
                    <measurement group_id="O2" value="28.48" spread="2.82"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="34.78" spread="3.57"/>
                    <measurement group_id="O2" value="33.13" spread="3.56"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>follow-up</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="37.06" spread="4.46"/>
                    <measurement group_id="O2" value="40.16" spread="4.46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>The study was designed as a standard dose-escalation study, dose-finding pilot study. The primary outcome measures were safety (hypercalcemia, hypophosphatemia and symptoms/hemodynamic measurements). A modified Fibronacci dose-escalation scheme was employed.</non_inferiority_desc>
            <p_value>.01</p_value>
            <p_value_desc>The reported p-value corresponds to change over time for the PTH 2 and PTH 4 pmol groups</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>The level of statistical significance was set at .05 (two-tailed)</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Parathyroid Hormone (1-84)</title>
        <description>pg/ml</description>
        <time_frame>baseline, daily up to Day 8 and follow-up</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Group 1</title>
            <description>PTH(1-34) 2 picomols (pmols)/kg/hr</description>
          </group>
          <group group_id="O2">
            <title>Group 2</title>
            <description>PTH(1-34) 4 picomoles/kg/hr for one week</description>
          </group>
        </group_list>
        <measure>
          <title>Parathyroid Hormone (1-84)</title>
          <description>pg/ml</description>
          <units>pg/ml</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
                <count group_id="O2" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20.90" spread="3.85"/>
                    <measurement group_id="O2" value="52.44" spread="12.88"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.86" spread="0.86"/>
                    <measurement group_id="O2" value="5.30" spread="2.11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.00" spread="0.00"/>
                    <measurement group_id="O2" value="3.38" spread="0.38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.12" spread="1.12"/>
                    <measurement group_id="O2" value="5.00" spread="2.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 5</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.64" spread="1.64"/>
                    <measurement group_id="O2" value="11.68" spread="6.28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 6</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.50" spread="0.50"/>
                    <measurement group_id="O2" value="6.34" spread="3.73"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 7</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.58" spread="0.58"/>
                    <measurement group_id="O2" value="6.68" spread="3.68"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.09" spread="0.09"/>
                    <measurement group_id="O2" value="3.00" spread="0.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>follow-up</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23.60" spread="2.29"/>
                    <measurement group_id="O2" value="35.20" spread="3.79"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>The study was designed as a standard dose-escalation study, dose-finding pilot study. The primary outcome measures were safety (hypercalcemia, hypophosphatemia and symptoms/hemodynamic measurements). A modified Fibronacci dose-escalation scheme was employed.</non_inferiority_desc>
            <p_value>&lt;.05</p_value>
            <p_value_desc>the reported p-values correspond to the decrease compared to baseline in all arms/groups at Days 2-8</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>The level of statistical significance was set at .05 (two-tailed)</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Fractional Excretion of Calcium</title>
        <description>% = (S Creatinine X U Calcium)/(S Calcium X U Creatinine)</description>
        <time_frame>baseline and daily</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Group 1</title>
            <description>PTH(1-34) 2 picomols (pmols)/kg/hr</description>
          </group>
          <group group_id="O2">
            <title>Group 2</title>
            <description>PTH(1-34) 4 picomoles/kg/hr for one week</description>
          </group>
        </group_list>
        <measure>
          <title>Fractional Excretion of Calcium</title>
          <description>% = (S Creatinine X U Calcium)/(S Calcium X U Creatinine)</description>
          <units>% of excretion</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
                <count group_id="O2" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.38" spread="1.42"/>
                    <measurement group_id="O2" value="1.80" spread="0.41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.83" spread="0.27"/>
                    <measurement group_id="O2" value="2.87" spread="0.71"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.28" spread="0.63"/>
                    <measurement group_id="O2" value="3.76" spread="0.63"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.82" spread="0.51"/>
                    <measurement group_id="O2" value="3.87" spread="0.89"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 5</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.90" spread="0.69"/>
                    <measurement group_id="O2" value="2.54" spread="0.42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 6</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.44" spread="0.57"/>
                    <measurement group_id="O2" value="3.49" spread="0.69"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.54" spread="0.70"/>
                    <measurement group_id="O2" value="4.58" spread="0.96"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>The study was designed as a standard dose-escalation study, dose-finding pilot study. The primary outcome measures were safety (hypercalcemia, hypophosphatemia and symptoms/hemodynamic measurements). A modified Fibronacci dose-escalation scheme was employed.</non_inferiority_desc>
            <p_value>.002</p_value>
            <p_value_desc>the reported p-value corresponds to the increase compared to baseline over time (days 2-8) in the PTH 2 pmol group</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>The level of statistical significance was set at .05 (two-tailed)</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>24 Hour Urine Calcium</title>
        <description>mg/gm creatinine</description>
        <time_frame>24 hours period from Day 7 to Day 8</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Group 1</title>
            <description>PTH(1-34) 2 picomols (pmols)/kg/hr</description>
          </group>
          <group group_id="O2">
            <title>Group 2</title>
            <description>PTH(1-34) 4 picomoles/kg/hr for one week</description>
          </group>
        </group_list>
        <measure>
          <title>24 Hour Urine Calcium</title>
          <description>mg/gm creatinine</description>
          <units>mg/gm creatinine</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
                <count group_id="O2" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="315.278845" spread="25.0352949"/>
                    <measurement group_id="O2" value="210.24827" spread="58.3459645"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Tubular Maximum for Phosphorous</title>
        <description>mg/dl</description>
        <time_frame>baseline and daily</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Group 1</title>
            <description>PTH(1-34) 2 picomols (pmols)/kg/hr</description>
          </group>
          <group group_id="O2">
            <title>Group 2</title>
            <description>PTH(1-34) 4 picomoles/kg/hr for one week</description>
          </group>
        </group_list>
        <measure>
          <title>Tubular Maximum for Phosphorous</title>
          <description>mg/dl</description>
          <units>mg/dl</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
                <count group_id="O2" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.80" spread="0.40"/>
                    <measurement group_id="O2" value="3.50" spread="0.28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.28" spread="0.16"/>
                    <measurement group_id="O2" value="3.30" spread="0.13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.37" spread="0.20"/>
                    <measurement group_id="O2" value="3.11" spread="0.24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.25" spread="0.27"/>
                    <measurement group_id="O2" value="3.66" spread="0.37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 5</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.19" spread="0.20"/>
                    <measurement group_id="O2" value="3.31" spread="0.22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 6</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.45" spread="0.16"/>
                    <measurement group_id="O2" value="3.25" spread="0.17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.52" spread="0.34"/>
                    <measurement group_id="O2" value="3.43" spread="0.10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>The study was designed as a standard dose-escalation study, dose-finding pilot study. The primary outcome measures were safety (hypercalcemia, hypophosphatemia and symptoms/hemodynamic measurements). A modified Fibronacci dose-escalation scheme was employed.</non_inferiority_desc>
            <p_value>.61</p_value>
            <p_value_desc>The reported p-value corresponds to change over time for the PTH 2 and PTH 4 pmol groups</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>The level of statistical significance was set at .05 (two-tailed)</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Serum Amino-terminal of Collagen- (sNTX)</title>
        <description>% change from baseline</description>
        <time_frame>baseline, daily, one week follow-up</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Group 1</title>
            <description>PTH(1-34) 2 picomols (pmols)/kg/hr</description>
          </group>
          <group group_id="O2">
            <title>Group 2</title>
            <description>PTH(1-34) 4 picomoles/kg/hr for one week</description>
          </group>
        </group_list>
        <measure>
          <title>Serum Amino-terminal of Collagen- (sNTX)</title>
          <description>% change from baseline</description>
          <units>% change from baseline</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
                <count group_id="O2" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" spread="0"/>
                    <measurement group_id="O2" value="0" spread="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="61.8428952" spread="18.6263576"/>
                    <measurement group_id="O2" value="77.4709521" spread="13.5088219"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="85.7699521" spread="27.761763"/>
                    <measurement group_id="O2" value="85.9288044" spread="12.9913176"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="96.3668762" spread="29.0312368"/>
                    <measurement group_id="O2" value="59.9595445" spread="18.6508014"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 5</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="107.517148" spread="29.2958519"/>
                    <measurement group_id="O2" value="83.3701575" spread="21.9993233"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 6</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="150.594712" spread="38.2863053"/>
                    <measurement group_id="O2" value="120.268081" spread="17.8645936"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 7</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="141.193285" spread="28.7484727"/>
                    <measurement group_id="O2" value="109.660098" spread="30.4136118"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="153.72039" spread="38.1279427"/>
                    <measurement group_id="O2" value="148.451289" spread="23.0512356"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>follow-up</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.06445076" spread="8.25178671"/>
                    <measurement group_id="O2" value="1.05486408" spread="11.8266679"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>The study was designed as a standard dose-escalation study, dose-finding pilot study. The primary outcome measures were safety (hypercalcemia, hypophosphatemia and symptoms/hemodynamic measurements). A modified Fibronacci dose-escalation scheme was employed.</non_inferiority_desc>
            <p_value>&lt;.008</p_value>
            <p_value_desc>The reported p-value corresponds to the % increase compared to baseline in all Arms/groups on Days 2-8</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>The level of statistical significance was set at .05 (two-tailed)</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>The study was designed as a standard dose-escalation study, dose-finding pilot study. The primary outcome measures were safety (hypercalcemia, hypophosphatemia and symptoms/hemodynamic measurements). A modified Fibronacci dose-escalation scheme was employed.</non_inferiority_desc>
            <p_value>&gt;0.05</p_value>
            <p_value_desc>The reported p-value corresponds the the % change from baseline at follow-up in all Arms/groups</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>The level of statistical significance was set at .05 (two-tailed)</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Serum Carboxy-terminal of Collagen- 1(sCTX)</title>
        <description>% change from baseline</description>
        <time_frame>baseline, daily, one week follow-up</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Group 1</title>
            <description>PTH(1-34) 2 picomols (pmols)/kg/hr</description>
          </group>
          <group group_id="O2">
            <title>Group 2</title>
            <description>PTH(1-34) 4 picomoles/kg/hr for one week</description>
          </group>
        </group_list>
        <measure>
          <title>Serum Carboxy-terminal of Collagen- 1(sCTX)</title>
          <description>% change from baseline</description>
          <units>% change from baseline</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
                <count group_id="O2" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" spread="0"/>
                    <measurement group_id="O2" value="0" spread="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="113.70" spread="37.63"/>
                    <measurement group_id="O2" value="104.07" spread="11.83"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="136.76" spread="45.34"/>
                    <measurement group_id="O2" value="112.11" spread="22.41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="142.66" spread="46.55"/>
                    <measurement group_id="O2" value="70.74" spread="37.02"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 5</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="165.97" spread="55.34"/>
                    <measurement group_id="O2" value="92.13" spread="36.22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 6</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="205.39" spread="60.11"/>
                    <measurement group_id="O2" value="141.66" spread="17.80"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 7</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="206.06" spread="60.02"/>
                    <measurement group_id="O2" value="168.77" spread="31.35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="225.04" spread="63.07"/>
                    <measurement group_id="O2" value="244.50" spread="25.28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>follow-up</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-6.78" spread="13.40"/>
                    <measurement group_id="O2" value="-11.82" spread="17.86"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>The study was designed as a standard dose-escalation study, dose-finding pilot study. The primary outcome measures were safety (hypercalcemia, hypophosphatemia and symptoms/hemodynamic measurements). A modified Fibronacci dose-escalation scheme was employed.</non_inferiority_desc>
            <p_value>&lt;.0001</p_value>
            <p_value_desc>The reported p-value corresponds to % change (increase) from baseline in all Arms/groups at Days 2-8.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>The level of statistical significance was set at .05 (two-tailed)</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>The study was designed as a standard dose-escalation study, dose-finding pilot study. The primary outcome measures were safety (hypercalcemia, hypophosphatemia and symptoms/hemodynamic measurements). A modified Fibronacci dose-escalation scheme was employed.</non_inferiority_desc>
            <p_value>&gt;0.05</p_value>
            <p_value_desc>The reported p-value corresponds the the % change from baseline at follow-up in all Arms/groups</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>The level of statistical significance was set at .05 (two-tailed)</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Amino-terminal Peptides of Procollagen- 1(P1NP)</title>
        <description>% change from baseline</description>
        <time_frame>baseline, daily, one week follow-up</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Group 1</title>
            <description>PTH(1-34) 2 picomols (pmols)/kg/hr</description>
          </group>
          <group group_id="O2">
            <title>Group 2</title>
            <description>PTH(1-34) 4 picomoles/kg/hr for one week</description>
          </group>
        </group_list>
        <measure>
          <title>Amino-terminal Peptides of Procollagen- 1(P1NP)</title>
          <description>% change from baseline</description>
          <units>% change from baseline</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
                <count group_id="O2" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" spread="0"/>
                    <measurement group_id="O2" value="0" spread="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-18.536953" spread="3.06129512"/>
                    <measurement group_id="O2" value="-16.118573" spread="9.23396676"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-31.14427" spread="3.986728"/>
                    <measurement group_id="O2" value="-35.577655" spread="3.47737847"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-32.942391" spread="1.15253446"/>
                    <measurement group_id="O2" value="-35.018736" spread="5.91933273"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 5</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-31.506308" spread="2.94297475"/>
                    <measurement group_id="O2" value="-35.309609" spread="6.61031904"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 6</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-36.35864" spread="5.71685066"/>
                    <measurement group_id="O2" value="-35.064188" spread="5.84391487"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 7</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-40.709396" spread="5.7024817"/>
                    <measurement group_id="O2" value="-30.58629" spread="3.41615735"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-39.046467" spread="4.79183284"/>
                    <measurement group_id="O2" value="-35.619862" spread="3.18918608"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>follow-up</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="31.4333667" spread="9.87895156"/>
                    <measurement group_id="O2" value="26.3367446" spread="16.1801142"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>The study was designed as a standard dose-escalation study, dose-finding pilot study. The primary outcome measures were safety (hypercalcemia, hypophosphatemia and symptoms/hemodynamic measurements). A modified Fibronacci dose-escalation scheme was employed.</non_inferiority_desc>
            <p_value>&lt;.0001</p_value>
            <p_value_desc>the reported p-value corresponds to % decrease compared to baseline at Days 2-8 in all Arms/groups</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>The level of statistical significance was set at .05 (two-tailed)</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>The study was designed as a standard dose-escalation study, dose-finding pilot study. The primary outcome measures were safety (hypercalcemia, hypophosphatemia and symptoms/hemodynamic measurements). A modified Fibronacci dose-escalation scheme was employed.</non_inferiority_desc>
            <p_value>.01</p_value>
            <p_value_desc>the reported p-value corresponds to % change from baseline at the follow-up visit in all Arms/groups</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>the reported p-value corresponds to % change from baseline at the follow-up visit in all Arms/groups</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Bone Specific Alkaline Phosphatase (BSAP)</title>
        <description>% change from baseline</description>
        <time_frame>baseline, daily, one week follow-up</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Group 1</title>
            <description>PTH(1-34) 2 picomols (pmols)/kg/hr</description>
          </group>
          <group group_id="O2">
            <title>Group 2</title>
            <description>PTH(1-34) 4 picomoles/kg/hr for one week</description>
          </group>
        </group_list>
        <measure>
          <title>Bone Specific Alkaline Phosphatase (BSAP)</title>
          <description>% change from baseline</description>
          <units>% change from baseline</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
                <count group_id="O2" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" spread="0"/>
                    <measurement group_id="O2" value="0" spread="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.35" spread="3.22"/>
                    <measurement group_id="O2" value="7.91" spread="7.47"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-5.61" spread="4.67"/>
                    <measurement group_id="O2" value="9.05" spread="12.82"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.34" spread="4.85"/>
                    <measurement group_id="O2" value="0.77" spread="9.93"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 5</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-8.75" spread="3.39"/>
                    <measurement group_id="O2" value="-2.19" spread="14.10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 6</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.42" spread="15.55"/>
                    <measurement group_id="O2" value="-8.89" spread="11.60"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 7</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.35" spread="12.69"/>
                    <measurement group_id="O2" value="-13.72" spread="12.96"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.09" spread="11.94"/>
                    <measurement group_id="O2" value="-9.91" spread="16.98"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>follow-up</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.08" spread="9.96"/>
                    <measurement group_id="O2" value="5.51" spread="8.28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>The study was designed as a standard dose-escalation study, dose-finding pilot study. The primary outcome measures were safety (hypercalcemia, hypophosphatemia and symptoms/hemodynamic measurements). A modified Fibronacci dose-escalation scheme was employed.</non_inferiority_desc>
            <p_value>&gt;.05</p_value>
            <p_value_desc>the reported p-value corresponds to % change compared to baseline at Days 2-8 in all Arms/groups</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>The level of statistical significance was set at .05 (two-tailed)</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>12 hours after the infusion was started then q 8 hours for 7 days, Follow-up 1 week after infusion complete</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Group 1</title>
          <description>PTH (1-34) 2 picomoles (pmols)/kg/hr</description>
        </group>
        <group group_id="E2">
          <title>Group 2</title>
          <description>PTH (1-34) 4 picomoles (pmols)/kg/hr</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>hypercalcemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>tachycardia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>IV infiltration</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Small number of subjects in each group Study limited to Caucasians Only one timepoint for follow-up was measure Study did not include saline infused controls</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Mara J Horwitz</name_or_title>
      <organization>University of Pittsburgh</organization>
      <phone>412-692-2848</phone>
      <email>horwitz@pitt.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

